NCT00914771 - Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects | Biotech Hunter

Enrollment

722

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions

Pandemic H5N1 Influenza

Interventions

BIOLOGICAL

H5N1 pandemic Influenza vaccine 3.75µg

2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 3.75µg H5N1 antigen

BIOLOGICAL

H5N1 pandemic Influenza vaccine 7.5µg

2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 7.5µg H5N1 antigen

Trial Locations (12)

"NZOZ Centrum Zdrowia Blonie", Bydgoszcz

"Prakytka Lekarzy Rodzinnych Salus", Katowice

Szpital Internistyczny, Krakow

Wojewodzki Specjalistyczny Szpital Dzieciecy im., Krakow

Samodyielny Publiczny ZOZ, Lubartów

"NZOZ Praktyka Lekarza Rodzinnego Eskulap", Lubin

Gazi Universitesi Tip Fakultesi, Ankara

Hacettepe Universitesi Tip Fakultesi Ic Hastaliklan, Ankara

T.C.S.B. Ankara Numune Egitim ve Arastirma, Ankara

T.C.S.B.Ataturk Egitim ve Arastirma Hastanesi, Ankara

Osmangazi Universitesi Tip Fakutesi, Eskişehir

Enfeksiyon Hastaliklari ve Klinik Mikeoviyloji, Izmir